The CT findings after interstitial radiation therapy for brain tumors have not been extensively described. We evaluated retrospectively the CT scans of 13 patients who were treated with brachytherapy for malignant glioma. We found no typical CT appearance that differentiates recurrent tumor from radiation effect. After undergoing brachytherapy, eight of the 13 patients scanned demonstrated enha...

PURPOSE SeedSelectron(®) v1.26b (Nucletron BV, The Netherlands) is an afterloader system used in prostate interstitial permanent brachytherapy with I-125 selectSeed seeds. It contains a diode array to assay all implanted seeds. Only one or two seeds can be extracted during the surgical procedure and assayed using a well chamber to check the manufacturer air-kerma strength (S(K)) and to calibrat...

Bladder cancer has been observed in patients after permanent iodine-125 brachytherapy （hereafter referred to as brachytherapy） for prostate cancer. We investigated secondary bladder brachytherapy. From January 2005 March 2021, a total of 1,478 underwent localized at Showa University Hospital and Koto Toyosu Hospital. A standardized incidence rate was calculated from the compared with national r...

Context: In absence of prospective randomized trials determining the optimal management of localized prostate cancer remains undefined. Objective: To develop and disseminate an update on outcome of different treatment modalities, recommendations and guidelines of transperineal prostate brachytherapy. Evidence acquisition: In the past decade, the average number of brachytherapy patients per cent...

Low-dose rate brachytherapy has become a mainstream treatment option for men diagnosed with prostate cancer because of excellent long-term treatment outcomes in low-, intermediate-, and high-risk patients. Largely due to patient lead advocacy for minimally invasive treatment options, high-quality prostate implants have become widely available in the US, Europe, and Japan. The reason that brachy...

INTRODUCTION We describe five patients receiving a re-implantation (RI) after post-operative dosimetry of the primary 125-I permanent prostate brachytherapy (BT) for prostate cancer revealed an insufficient dose coverage. MATERIALS AND METHODS Five out of 222 consecutive patients treated (from March, 2001 to August, 2012) with 125-I BT, received a RI after dosimetric verification by CT and MR...

PURPOSE A process for prostate high-dose-rate (HDR) brachytherapy was developed and implemented successfully in the community hospital setting. The practical aspects of the program are reviewed and may serve as a foundation for clinics interested in offering this clinical service. METHODS AND MATERIALS A generic needle distribution geometry was established to accommodate target volumes of var...

PURPOSE To outline the evolution of computerized brachytherapy treatment planning in the United States through a review of technological developments and clinical practice refinements. MATERIAL AND METHODS A literature review was performed and interviews were conducted with six participants in the development of computerized treatment planning for brachytherapy. RESULTS Computerized brachyt...

PURPOSE To evaluate a new calculation model estimating the equivalent dose at 2 Gy (EQD2) taking into account dose gradient in high dose rate interstitial brachytherapy (HDRIB). MATERIAL AND METHODS Forty dose-volume histograms (DVHs) of breast (20 pts) and prostate (20 pts) cancer dose distributions were reviewed. Physical prescribed doses (PPD) were 34 Gy (10f/5d) and 18 Gy (6f/2d) for brea...